Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China
· Delayed Price · Currency is CNY 29.55
-0.62 (-2.06%)
At close: Mar 9, 2026
SHA:688217 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 174 | 234.95 | 246.05 | 416.06 | 270.59 | Upgrade
|
| Other Revenue | - | 7.36 | 12.16 | 8.24 | 20.36 | Upgrade
|
| Revenue | 174 | 242.31 | 258.21 | 424.3 | 290.95 | Upgrade
|
| Revenue Growth (YoY) | -28.19% | -6.16% | -39.14% | 45.83% | 2.11% | Upgrade
|
| Cost of Revenue | - | 62.84 | 70.56 | 166.6 | 78.83 | Upgrade
|
| Gross Profit | 174 | 179.47 | 187.65 | 257.7 | 212.12 | Upgrade
|
| Selling, General & Admin | - | 127.32 | 120.9 | 109.76 | 115.31 | Upgrade
|
| Research & Development | - | 62.47 | 69.8 | 64.43 | 68.64 | Upgrade
|
| Other Operating Expenses | 227.5 | 2.18 | 2 | 1.14 | 0.78 | Upgrade
|
| Operating Expenses | 227.5 | 198.62 | 197.73 | 184.88 | 185.09 | Upgrade
|
| Operating Income | -53.5 | -19.15 | -10.08 | 72.81 | 27.04 | Upgrade
|
| Interest Expense | - | -0.88 | -0.83 | -0.55 | -0.49 | Upgrade
|
| Interest & Investment Income | - | 4.79 | 6.49 | 4.74 | 4.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.66 | 0.84 | 4.69 | -1.54 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.93 | -0.26 | -0.58 | -0.35 | -0.75 | Upgrade
|
| EBT Excluding Unusual Items | -54.43 | -14.85 | -4.15 | 81.34 | 28.34 | Upgrade
|
| Impairment of Goodwill | - | -14.31 | -7.5 | -13.39 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.87 | 0.33 | 0.61 | 2.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.12 | 0.84 | -0.01 | -0.1 | Upgrade
|
| Asset Writedown | - | -2.37 | -0.14 | -0.77 | - | Upgrade
|
| Other Unusual Items | - | 2.05 | 1.22 | 3.7 | 12.12 | Upgrade
|
| Pretax Income | -54.43 | -28.47 | -9.4 | 71.48 | 42.45 | Upgrade
|
| Income Tax Expense | -4.55 | -2.57 | -4.6 | 5.56 | 2.37 | Upgrade
|
| Earnings From Continuing Operations | -49.88 | -25.91 | -4.8 | 65.92 | 40.08 | Upgrade
|
| Minority Interest in Earnings | - | 10.14 | 12.74 | -25.45 | 7.25 | Upgrade
|
| Net Income | -49.88 | -15.76 | 7.93 | 40.47 | 47.33 | Upgrade
|
| Net Income to Common | -49.88 | -15.76 | 7.93 | 40.47 | 47.33 | Upgrade
|
| Net Income Growth | - | - | -80.41% | -14.49% | 22.26% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 56 | 57 | 55 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 56 | 57 | 55 | 50 | Upgrade
|
| Shares Change (YoY) | -1.55% | -0.61% | 2.17% | 11.28% | 19.69% | Upgrade
|
| EPS (Basic) | -0.90 | -0.28 | 0.14 | 0.73 | 0.95 | Upgrade
|
| EPS (Diluted) | -0.90 | -0.28 | 0.14 | 0.73 | 0.95 | Upgrade
|
| EPS Growth | - | - | -80.82% | -23.16% | 2.15% | Upgrade
|
| Free Cash Flow | - | 20.57 | -64 | -33.5 | -17.63 | Upgrade
|
| Free Cash Flow Per Share | - | 0.36 | -1.13 | -0.60 | -0.35 | Upgrade
|
| Dividend Per Share | - | - | 0.180 | - | - | Upgrade
|
| Gross Margin | 100.00% | 74.07% | 72.67% | 60.73% | 72.91% | Upgrade
|
| Operating Margin | -30.75% | -7.90% | -3.91% | 17.16% | 9.29% | Upgrade
|
| Profit Margin | -28.67% | -6.51% | 3.07% | 9.54% | 16.27% | Upgrade
|
| Free Cash Flow Margin | - | 8.49% | -24.79% | -7.90% | -6.06% | Upgrade
|
| EBITDA | -13.59 | 20.76 | 29.15 | 103.68 | 60.04 | Upgrade
|
| EBITDA Margin | -7.81% | 8.57% | 11.29% | 24.44% | 20.64% | Upgrade
|
| D&A For EBITDA | 39.91 | 39.91 | 39.23 | 30.86 | 33 | Upgrade
|
| EBIT | -53.5 | -19.15 | -10.08 | 72.81 | 27.04 | Upgrade
|
| EBIT Margin | -30.75% | -7.90% | -3.91% | 17.16% | 9.29% | Upgrade
|
| Effective Tax Rate | - | - | - | 7.78% | 5.58% | Upgrade
|
| Revenue as Reported | - | 242.31 | 258.21 | 424.3 | 290.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.